From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis
The gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk factors, gut dysbiosis, aberrant microbial metabolites, and neuro-immune pathway disruptions have been imp...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1630726/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320138725130240 |
|---|---|
| author | Ze-qiang Liu Xiao-ying Yang Jia-hong Chen Si-cheng Ge Si-cheng Ge Shi-xue Dai Shi-xue Dai Sheng-huang Zhu Zhi-yong Xian Zhi-yong Xian |
| author_facet | Ze-qiang Liu Xiao-ying Yang Jia-hong Chen Si-cheng Ge Si-cheng Ge Shi-xue Dai Shi-xue Dai Sheng-huang Zhu Zhi-yong Xian Zhi-yong Xian |
| author_sort | Ze-qiang Liu |
| collection | DOAJ |
| description | The gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk factors, gut dysbiosis, aberrant microbial metabolites, and neuro-immune pathway disruptions have been implicated in tumorigenesis and progression. Short-chain fatty acids (SCFAs), microbial-derived metabolites, are shown to indirectly modulate tumor behavior through immune microenvironment regulation and inflammatory response attenuation. Cross-organ crosstalk is further mediated by neural pathways (e.g., vagal signaling) and shared receptors, including the Farnesoid X Receptor (FXR) and Toll-like Receptor 4 (TLR4). Novel therapies leveraging microbial ecology principles demonstrate potential, including immune checkpoint inhibitors combined with microbiota modulation (e.g., Parabacteroides distasonis-enhanced PD-1 efficacy), probiotics to reverse chemoresistance, and microbiota reprogramming for SCFA-targeted strategies. However, molecular mechanisms underlying GBA-host interactions remain poorly characterized. Clinical translation is hindered by limited cohort sizes and interindividual heterogeneity. Current studies, while revealing partial pathways, face methodological inconsistencies, particularly in urinary microbiome profiling, and a lack of longitudinal human data. Future breakthroughs will require multi-omics integration, organoid-based models, and interdisciplinary collaboration to address these gaps. |
| format | Article |
| id | doaj-art-7adb216e7aa04687aa502e2b084e6d23 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-7adb216e7aa04687aa502e2b084e6d232025-08-20T03:50:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.16307261630726From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesisZe-qiang Liu0Xiao-ying Yang1Jia-hong Chen2Si-cheng Ge3Si-cheng Ge4Shi-xue Dai5Shi-xue Dai6Sheng-huang Zhu7Zhi-yong Xian8Zhi-yong Xian9The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, ChinaThe First School of Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi, ChinaDepartment of Urology, Cancer Center, National Regional Medical Center, Guangdong Provincial People’s Hospital Ganzhou Hospital, Ganzhou, Jiangxi, ChinaDepartment of Gastroenterology, Guangdong Provincial Geriatrics Institute, National Key Clinical Specialty, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, ChinaDepartment of Gastroenterology, Geriatric Center, National Regional Medical Center, Guangdong Provincial People’s Hospital Ganzhou Hospital, Ganzhou, Jiangxi, ChinaDepartment of Urology, Cancer Center, National Regional Medical Center, Guangdong Provincial People’s Hospital Ganzhou Hospital, Ganzhou, Jiangxi, ChinaDepartment of Urology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, ChinaDepartment of Urology, Cancer Center, National Regional Medical Center, Guangdong Provincial People’s Hospital Ganzhou Hospital, Ganzhou, Jiangxi, ChinaThe gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk factors, gut dysbiosis, aberrant microbial metabolites, and neuro-immune pathway disruptions have been implicated in tumorigenesis and progression. Short-chain fatty acids (SCFAs), microbial-derived metabolites, are shown to indirectly modulate tumor behavior through immune microenvironment regulation and inflammatory response attenuation. Cross-organ crosstalk is further mediated by neural pathways (e.g., vagal signaling) and shared receptors, including the Farnesoid X Receptor (FXR) and Toll-like Receptor 4 (TLR4). Novel therapies leveraging microbial ecology principles demonstrate potential, including immune checkpoint inhibitors combined with microbiota modulation (e.g., Parabacteroides distasonis-enhanced PD-1 efficacy), probiotics to reverse chemoresistance, and microbiota reprogramming for SCFA-targeted strategies. However, molecular mechanisms underlying GBA-host interactions remain poorly characterized. Clinical translation is hindered by limited cohort sizes and interindividual heterogeneity. Current studies, while revealing partial pathways, face methodological inconsistencies, particularly in urinary microbiome profiling, and a lack of longitudinal human data. Future breakthroughs will require multi-omics integration, organoid-based models, and interdisciplinary collaboration to address these gaps.https://www.frontiersin.org/articles/10.3389/fonc.2025.1630726/fullgut-bladder axisbladder cancermicrobiotadysbiosisprobiotics |
| spellingShingle | Ze-qiang Liu Xiao-ying Yang Jia-hong Chen Si-cheng Ge Si-cheng Ge Shi-xue Dai Shi-xue Dai Sheng-huang Zhu Zhi-yong Xian Zhi-yong Xian From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis Frontiers in Oncology gut-bladder axis bladder cancer microbiota dysbiosis probiotics |
| title | From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis |
| title_full | From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis |
| title_fullStr | From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis |
| title_full_unstemmed | From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis |
| title_short | From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis |
| title_sort | from dysbiosis to precision therapy decoding the gut bladder axis in bladder carcinogenesis |
| topic | gut-bladder axis bladder cancer microbiota dysbiosis probiotics |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1630726/full |
| work_keys_str_mv | AT zeqiangliu fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT xiaoyingyang fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT jiahongchen fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT sichengge fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT sichengge fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT shixuedai fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT shixuedai fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT shenghuangzhu fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT zhiyongxian fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis AT zhiyongxian fromdysbiosistoprecisiontherapydecodingthegutbladderaxisinbladdercarcinogenesis |